Red blood cell (RBC) transfusion practices in neonatal intensive care units are variable. Clinicians and centers differ in when they choose to transfuse infants, and no single universal approach is consistently applied across NICUs. This variability reflects differences in interpretation of available evidence, local protocols, and patient populations encountered in practice.
A recurring challenge for neonatal clinicians is determining which infants should receive an RBC transfusion and identifying the specific hemoglobin or hematocrit thresholds that should trigger transfusion. Threshold-based decision-making remains common, but the precise cutoff values and how they are adjusted for clinical context vary. The review highlights that deciding to transfuse involves integrating laboratory values with the infant’s clinical status rather than relying solely on numeric thresholds.
For premature infants, there are some well-conducted randomized controlled trials and short-term follow-up studies. These trials provide a more robust evidence base relative to what exists for term infants and inform transfusion strategies in many NICUs. However, even within the preterm population, clinicians must interpret trial results in the context of individual patient comorbidities and the specifics of the trials’ inclusion criteria and outcomes. The review summarizes these trial data and their implications for practice, while noting that evidence is not uniformly comprehensive across all clinical scenarios.
Data on term infants are limited. The literature specifically addressing RBC transfusion in full-term neonates consists largely of heterogeneous observational studies and extrapolation from broader pediatric critical care expert consensus recommendations. There is a lack of neonatal-specific randomized trials focused on term infants, and most guidance for this group derives from studies and guidelines intended for a wider pediatric critical care population rather than term neonates exclusively.
Critically ill infants in the NICU present with varying comorbidities that influence transfusion decisions. The review discusses how unique characteristics—such as underlying cardiorespiratory instability, ongoing blood loss, or other organ dysfunction—should be weighed when considering RBC transfusion. The authors emphasize that transfusion decisions must be individualized, incorporating both objective measures (for example, hemoglobin or hematocrit) and the infant’s clinical trajectory.
When clinicians proceed with RBC transfusion, specific procedural considerations are important. The review covers practical aspects such as the transfusion volume, infusion rate, and product preparation. These operational details can affect efficacy and safety and often form part of institutional transfusion protocols. The article summarizes current considerations clinicians should review before and during transfusion.
Reducing the need for RBC transfusions is an important goal in neonatal care. The review outlines strategies aimed at minimizing transfusion exposure, though specific measures and their evidence base vary. Approaches may include minimizing iatrogenic blood loss from sampling, optimizing erythropoiesis where appropriate, and applying restrictive transfusion strategies informed by trial data in preterm infants. The review notes that the strength of evidence for these strategies differs between preterm and term populations.
The article provides general strategies to guide the neonatologist in deciding when to transfuse RBCs. These strategies synthesize available trial data (mainly for preterm infants), observational studies, and expert consensus, particularly where neonatal-specific evidence is limited. The guidance emphasizes individualized decision-making that accounts for both numeric thresholds and the infant’s overall clinical picture.
The review highlights important limitations in the literature. While randomized trials offer data for premature infants, there is a paucity of high-quality neonatal-specific evidence for term infants. Much of the information guiding transfusion in term neonates is derived from heterogeneous observational studies or from expert consensus guidelines that address a broader pediatric critical care population. The authors underscore the need for further neonatal-focused research to clarify optimal transfusion thresholds, procedural details, and strategies to reduce transfusion exposure across both preterm and term infants.
Conclusion
In summary, RBC transfusion in the NICU remains an area of practice variability and evolving evidence. Clinicians should apply available randomized trial data for preterm infants where appropriate, recognize the limited neonatal-specific evidence for term infants, and individualize transfusion decisions based on both laboratory values and the infant’s clinical status. Practical considerations regarding transfusion volume, rate, and preparation, together with strategies to minimize transfusion need, are important components of safe neonatal transfusion practice.
Note: This summary is based on the article abstract. Detailed trial data, numeric thresholds, and specific protocol recommendations were not reported in the abstract portion of the source and therefore are not included here.